Kemp Dolliver
Stock Analyst at Brookline Capital
(0.30)
# 4,011
Out of 4,818 analysts
17
Total ratings
25%
Success rate
-28.35%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $4.26 | +299.06% | 1 | Dec 5, 2024 | |
| EYEN Eyenovia | Downgrades: Hold | n/a | $1.10 | - | 2 | Nov 15, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $0.46 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $0.70 | +414.29% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.97 | +1,112.12% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.50 | +1,993.33% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $0.23 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $99.70 | +0.30% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.30 | +2,378.26% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $2.95 | +748.90% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.58 | +184.95% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.94 | +747.10% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $1.13 | +400.00% | 1 | Feb 2, 2022 |
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $4.26
Upside: +299.06%
Eyenovia
Nov 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.10
Upside: -
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.46
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $0.70
Upside: +414.29%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.97
Upside: +1,112.12%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.50
Upside: +1,993.33%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.23
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $99.70
Upside: +0.30%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.30
Upside: +2,378.26%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.95
Upside: +748.90%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $6.58
Upside: +184.95%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.94
Upside: +747.10%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $1.13
Upside: +400.00%